Leukapheresis Market by Product (Devices, Filters, Membrane Separators), Leukopak (Mobilized, Non-Mobilized), Indication (ALL, NHL, Multiple Myeloma), Application (Research, Therapeutic), End User (Hospitals, Pharma, Biotech) & Region - Global Forecast to 2028
The global leukapheresis products market is predicted to reach USD 100 million by 2028 from USD 70 million in 2023, at a CAGR of 8.3%. The global leukopaks market is predicted to reach USD 1020 million by 2028 from USD 200 million in 2023, at a CAGR of 38.1%. Due to the cases of leukemia rising globally, and rising need for leukopaks in clinical trials and other research applications, the leukapheresis market is expected to grow in the forecast period.
“The research applications accounted for a larger share of the leukapheresis products market.”
By, application, the leukpaheresis products market is segmented into research applications and therapeutic applications. The research applications segment accounted for the larger share of the leukapheresis products market in 2022. The growing development of cell-based immunotherapies and rising demand for leukapheresis-derived primary cells in drug development are some of the major factors driving the growth of the leukapheresis products market during the forecast period.
“The academic & research institutes segment accounted for the largest share of the leukopaks market.”
By end user, the leukopaks market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, and contract research organizations. In 2022, the academic & research institutes segment accounted for the largest share of the leukapheresis products market. The increasing number of industry-academic partnerships for conducting research on cell-based cancer therapies is driving the growth of this end-user segment.
“Asia Pacific will grow at highest CAGR during the forecast period.“
In 2022, Asia Pacific will grow at highest CAGR during the forecast period. The Asia Pacific region is expected to be the fastest growing region in the forecast period. The increasing CAR-T cell therapy research and rising number of pharma & biotech companies and research institutes in China are some of the factors driving market growth. In 2022, China accounted for the largest share of the Asia Pacific leukopaks market. The large share of China can be attributed mainly to the presence of a number of cellular immunotherapy companies in the country.
The break-up of the profile of primary participants in the leukapheresis products market: Supply-side
Some prominent players in the leukopaks market are Discovery Life Sciences (US), StemExpress, LLC (US), Charles River Laboratories International, Inc. (US), Caltag Medsystems Limited (UK), Lonza Group AG (Switzerland), and ZenBio (US).
Research Coverage:
The report analyzes the leukapheresis market and aims at estimating the market size and future growth potential of this market based on various segments such as product, and region. The report also includes competitive analysis of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall leukapheresis market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report provides insights into the following pointers:
“The research applications accounted for a larger share of the leukapheresis products market.”
By, application, the leukpaheresis products market is segmented into research applications and therapeutic applications. The research applications segment accounted for the larger share of the leukapheresis products market in 2022. The growing development of cell-based immunotherapies and rising demand for leukapheresis-derived primary cells in drug development are some of the major factors driving the growth of the leukapheresis products market during the forecast period.
“The academic & research institutes segment accounted for the largest share of the leukopaks market.”
By end user, the leukopaks market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, and contract research organizations. In 2022, the academic & research institutes segment accounted for the largest share of the leukapheresis products market. The increasing number of industry-academic partnerships for conducting research on cell-based cancer therapies is driving the growth of this end-user segment.
“Asia Pacific will grow at highest CAGR during the forecast period.“
In 2022, Asia Pacific will grow at highest CAGR during the forecast period. The Asia Pacific region is expected to be the fastest growing region in the forecast period. The increasing CAR-T cell therapy research and rising number of pharma & biotech companies and research institutes in China are some of the factors driving market growth. In 2022, China accounted for the largest share of the Asia Pacific leukopaks market. The large share of China can be attributed mainly to the presence of a number of cellular immunotherapy companies in the country.
The break-up of the profile of primary participants in the leukapheresis products market: Supply-side
- By Company Type (Supply-side): Tier 1: 35%, Tier 2: 30%, and Tier 3: 35%
- By Designation: C-level: 30%, Director-level: 30%, and Others: 40%
- By Region: North America: 45%, Europe: 25%, Asia-Pacific: 20%, and Rest of the World: 10%
- By Company Type (Supply-side): Tier 1: 44%, Tier 2: 36%, and Tier 3: 20%
- By Designation: C-level: 44%, Director-level: 33%, and Others: 23%
- By Region: North America: 40%, Europe: 25%, Asia-Pacific: 20%, and Rest of the World: 15%
Some prominent players in the leukopaks market are Discovery Life Sciences (US), StemExpress, LLC (US), Charles River Laboratories International, Inc. (US), Caltag Medsystems Limited (UK), Lonza Group AG (Switzerland), and ZenBio (US).
Research Coverage:
The report analyzes the leukapheresis market and aims at estimating the market size and future growth potential of this market based on various segments such as product, and region. The report also includes competitive analysis of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall leukapheresis market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report provides insights into the following pointers:
- Analysis of key drivers (rising incidence and prevalence of leukemia, increasing number of blood donations, increased demand for leukopaks in clinical research), restraints (high cost of therapeutic leukapheresis and leukopaks, stringent donor recruitment criteria, complications associated with therapeutic leukapheresis), opportunities (leukapheresis for pediatric patients, emerging economies with investments from academic institutes, pharma-biotech companies, and leading players), and challenges (blood transfusion safety in emerging countries) influencing the growth of the leukapheresis market
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the leukapheresis market
- Market Development: Comprehensive information on the lucrative emerging markets by type, usage, end user and region.
- Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global leukapheresis market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players like Asahi Kasei Corporation (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Terumo BCT, Inc. (US), Macopharma SA (France), and Miltenyi Biotec (Germany) in the global leukapheresis market.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 TYPE
1.2.2 APPLICATION
1.2.3 END USER
1.2.4 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
TABLE 1 STANDARD CURRENCY CONVERSION RATES
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
1.7 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Insights from primary experts
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS (LEUKAPHERESIS PRODUCTS AND LEUKOPAKS MARKET)
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION (LEUKAPHERESIS PRODUCTS MARKET)
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, AND REGION (LEUKAPHERESIS PRODUCTS MARKET)
FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION (LEUKOPAKS MARKET)
FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, AND REGION (LEUKOPAKS MARKET)
2.2 MARKET SIZE ESTIMATION: LEUKAPHERESIS PRODUCTS MARKET
FIGURE 8 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 9 REVENUE SHARE ANALYSIS ILLUSTRATION: TERUMO CORPORATION (2022)
FIGURE 10 REVENUE ANALYSIS OF TOP FOUR COMPANIES: LEUKAPHERESIS PRODUCTS MARKET (2022)
FIGURE 11 DEMAND-SIDE APPROACH: LEUKAPHERESIS PRODUCTS MARKET (2022)
FIGURE 12 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2023–2028)
FIGURE 13 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS (LEUKAPHERESIS PRODUCTS MARKET)
FIGURE 14 TOP-DOWN APPROACH
2.3 MARKET SIZE ESTIMATION: LEUKOPAKS MARKET
FIGURE 15 VOLUME ESTIMATION OF LEUKOPAKS MARKET
FIGURE 16 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS (LEUKOPAKS MARKET)
FIGURE 17 TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 18 MARKET DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE ANALYSIS
2.6 RESEARCH ASSUMPTIONS
2.7 RISK ASSESSMENT
TABLE 2 RISK ASSESSMENT: LEUKAPHERESIS PRODUCTS AND LEUKOPAKS MARKETS
2.8 METHODOLOGY-RELATED LIMITATIONS
2.9 RECESSION IMPACT ANALYSIS
3 EXECUTIVE SUMMARY
FIGURE 19 LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 20 LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 21 LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 22 LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 23 LEUKOPAKS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 24 LEUKOPAKS MARKET, BY INDICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 25 LEUKOPAKS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 26 GEOGRAPHIC SNAPSHOT: LEUKAPHERESIS PRODUCTS MARKET
FIGURE 27 GEOGRAPHIC SNAPSHOT: LEUKOPAKS MARKET
4 PREMIUM INSIGHTS
4.1 LEUKAPHERESIS PRODUCTS MARKET: OVERVIEW
FIGURE 28 INCREASING INCIDENCE AND PREVALENCE OF LEUKEMIA TO DRIVE MARKET
4.2 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE AND COUNTRY
FIGURE 29 DISPOSABLES TO DOMINATE NORTH AMERICAN LEUKAPHERESIS PRODUCTS MARKET IN 2022
4.3 LEUKAPHERESIS PRODUCTS MARKET: GEOGRAPHIC MIX
FIGURE 30 CHINA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
4.4 LEUKAPHERESIS PRODUCTS MARKET: REGIONAL MIX
FIGURE 31 NORTH AMERICA DOMINATED MARKET IN 2022
4.5 LEUKOPAKS MARKET: OVERVIEW
FIGURE 32 RISING DEMAND FOR LEUKOPAKS FOR USE IN RESEARCH APPLICATIONS TO DRIVE MARKET
4.6 NORTH AMERICA: LEUKOPAKS MARKET, BY PRODUCT AND COUNTRY
FIGURE 33 MOBILIZED LEUKOPAKS COMMANDED LARGEST SHARE OF MARKET IN 2022
4.7 LEUKOPAKS MARKET: GEOGRAPHIC MIX
FIGURE 34 CHINA TO RECORD HIGHEST GROWTH DURING FORECAST PERIOD
4.8 LEUKOPAKS MARKET: REGIONAL MIX
FIGURE 35 ASIA PACIFIC MARKET TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 36 LEUKAPHERESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising incidence and prevalence of leukemia
FIGURE 37 ESTIMATED NUMBER OF NEW LEUKEMIA CASES, BY REGION (2020–2040)
FIGURE 38 ESTIMATED NUMBER OF LEUKEMIA DEATHS, BY REGION (2020–2040)
5.2.1.2 Increasing blood donation
5.2.1.3 Growing demand for leukopaks in clinical research
FIGURE 39 GROWTH IN NUMBER OF CAR-T CLINICAL TRIALS, 2009–2020
FIGURE 40 NUMBER OF CAR-T THERAPY CLINICAL TRIALS: US VS. CHINA, 2022
5.2.2 RESTRAINTS
5.2.2.1 High cost of therapeutic leukapheresis and leukopaks
TABLE 3 COST OF LEUKOPAKS, BY TYPE
5.2.2.2 Stringent donor recruitment criteria
TABLE 4 DONOR SELECTION CRITERIA
TABLE 5 FREQUENCY OF BLOOD DONATION FROM HEALTHY DONORS
5.2.2.3 Dearth of skilled professionals
5.2.2.4 Complications associated with therapeutic leukapheresis
5.2.2.5 Long duration of procedure
5.2.2.6 High cost of cellular immunotherapies and lack of favorable reimbursement
5.2.3 OPPORTUNITIES
5.2.3.1 Growing focus on leukapheresis for pediatric patients
5.2.3.2 Increasing investments in CAR-T therapies in emerging economies
5.2.3.3 Gaps in current leukapheresis technologies
5.2.4 CHALLENGES
5.2.4.1 Concerns related to safety of blood transfusion in emerging economies
5.3 PORTER’S FIVE FORCES ANALYSIS
FIGURE 41 PORTER’S FIVE FORCES ANALYSIS: LEUKAPHERESIS MARKET
TABLE 6 LEUKAPHERESIS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.3.1 THREAT FROM NEW ENTRANTS
5.3.2 THREAT FROM SUBSTITUTES
5.3.3 BARGAINING POWER OF SUPPLIERS
5.3.4 BARGAINING POWER OF BUYERS
5.3.5 INTENSITY OF COMPETITIVE RIVALRY
5.4 INDUSTRY TRENDS
5.4.1 INCREASING COLLABORATIONS BETWEEN PHARMA AND BIOTECH COMPANIES
TABLE 7 RECENT DEVELOPMENTS RELATED TO CAR-T THERAPY
5.4.2 INTRODUCTION OF CUSTOMIZABLE CRYOPRESERVED LEUKOPAKS
5.5 TECHNOLOGY ANALYSIS
5.5.1 KEY TECHNOLOGIES
5.5.1.1 Centrifugal-based leukapheresis
5.5.1.2 Membrane-based leukapheresis
TABLE 8 MATERIALS USED FOR LEUKOCYTE FILTRATION AND SURFACE MODIFICATION TECHNIQUES APPLIED FOR ENHANCED SEPARATION
5.5.2 EMERGING TECHNOLOGIES
5.5.2.1 Adsorption-based leukapheresis
5.5.2.2 Microfluidic devices for leukapheresis
5.5.2.3 Integration of AI in leukapheresis treatment
5.6 PRICING ANALYSIS (LEUKOPAKS MARKET)
TABLE 9 ASP OF NON-MOBILIZED LEUKOPAKS
TABLE 10 ASP OF MOBILIZED LEUKOPAKS
TABLE 11 ASP OF MOBILIZED ISOLATED CELLS
5.7 KEY CONFERENCES AND EVENTS, 2023–2024
TABLE 12 LEUKAPHERESIS MARKET: CONFERENCES AND EVENTS
5.8 REGULATORY ANALYSIS (LEUKAPHERESIS PRODUCTS MARKET)
5.8.1 NORTH AMERICA
5.8.1.1 US
5.8.1.2 Canada
5.8.2 EUROPE
5.8.3 ASIA PACIFIC
5.8.3.1 Japan
5.8.3.2 China
5.9 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 17 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.10 REGULATORY ANALYSIS (LEUKOPAKS MARKET)
5.10.1 US
TABLE 18 LIST OF FDA-APPROVED CAR-T THERAPEUTICS
5.10.2 EUROPE
5.10.3 JAPAN
5.10.4 INDIA
5.11 VALUE CHAIN ANALYSIS
FIGURE 42 VALUE CHAIN: LEUKAPHERESIS MARKET (LEUKAPHERESIS SYSTEMS)
5.12 SUPPLY CHAIN ANALYSIS
FIGURE 43 LEUKAPHERESIS MARKET: STAKEHOLDERS IN SUPPLY CHAIN
5.13 ECOSYSTEM ANALYSIS
FIGURE 44 LEUKAPHERESIS MARKET: ECOSYSTEM MAP
TABLE 19 LEUKAPHERESIS MARKET: ECOSYSTEM
5.14 HS CODES: CENTRIFUGAL DEVICES AND MEMBRANE SEPARATORS
5.15 PATENT ANALYSIS
5.15.1 PATENT PUBLICATION TRENDS IN LEUKAPHERESIS PRODUCTS MARKET
FIGURE 45 GLOBAL PATENT PUBLICATION TRENDS IN LEUKAPHERESIS PRODUCTS MARKET, JANUARY 2019–AUGUST 2023
5.15.2 PATENT PUBLICATION TRENDS IN LEUKOPAKS MARKET
FIGURE 46 GLOBAL PATENT PUBLICATION TRENDS IN LEUKOPAKS MARKET, JANUARY 2019–AUGUST 2023
5.15.3 TOP APPLICANTS FOR LEUKAPHERESIS PRODUCT PATENTS
FIGURE 47 TOP APPLICANTS FOR LEUKAPHERESIS PRODUCT PATENTS, JANUARY 2019–AUGUST 2023
5.15.4 TOP APPLICANTS FOR LEUKOPAK PATENTS
FIGURE 48 TOP APPLICANTS FOR LEUKOPAK PATENTS, JANUARY 2019–AUGUST 2023
5.15.5 JURISDICTION ANALYSIS: TOP COUNTRIES FOR LEUKAPHERESIS MARKET PATENTS
FIGURE 49 JURISDICTION ANALYSIS: TOP COUNTRIES FOR LEUKAPHERESIS PATENTS, JANUARY 2019–AUGUST 2023
FIGURE 50 JURISDICTION ANALYSIS: TOP COUNTRIES FOR LEUKOPAK PATENTS, JANUARY 2019–AUGUST 2023
5.15.6 TOP PATENT APPLICANTS/OWNERS
FIGURE 51 TOP APPLICANTS AND OWNERS FOR LEUKAPHERESIS PRODUCT PATENTS, JANUARY 2019–AUGUST 2023
FIGURE 52 TOP APPLICANTS AND OWNERS FOR LEUKOPAK PATENTS, JANUARY 2019–AUGUST 2023
TABLE 20 LEUKAPHERESIS PRODUCTS MARKET: MAJOR PATENTS (2020–2022)
TABLE 21 LEUKOPAKS MARKET: MAJOR PATENTS (2019–2022)
5.16 KEY STAKEHOLDERS AND BUYING CRITERIA
5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 53 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR LEUKAPHERESIS PRODUCTS AND LEUKOPAKS
TABLE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR LEUKAPHERESIS PRODUCTS AND LEUKOPAKS
5.16.2 BUYING CRITERIA
FIGURE 54 KEY BUYING CRITERIA FOR LEUKAPHERESIS PRODUCTS AND LEUKOPAKS
TABLE 23 KEY BUYING CRITERIA FOR LEUKAPHERESIS PRODUCTS AND LEUKOPAKS
5.17 CASE STUDIES
TABLE 24 CASE STUDY 1: ESTIMATING MARKET SIZE OF LEUKAPHERESIS PRODUCTS AND MARKET SHARE ANALYSIS FOR KEY PRODUCTS AT COUNTRY LEVEL
TABLE 25 CASE STUDY 2: ESTIMATING MARKET SIZE OF LEUKOPAKS AND MARKET SHARE ANALYSIS FOR KEY PRODUCTS AT COUNTRY LEVEL
5.18 ADJACENT MARKET ANALYSIS
5.18.1 PLASMA FRACTIONATION MARKET
FIGURE 55 PLASMA FRACTIONATION MARKET OVERVIEW
5.18.2 APHERESIS MARKET
FIGURE 56 APHERESIS MARKET OVERVIEW
6 LEUKAPHERESIS PRODUCTS MARKET, BY TYPE
6.1 INTRODUCTION
TABLE 26 LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 27 LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.2 DISPOSABLES
6.2.1 RECURRENT DEMAND TO BOOST SEGMENT
TABLE 28 LEUKOREDUCTION FILTER MANUFACTURERS
TABLE 29 LEUKAPHERESIS COLUMN AND CELL SEPARATOR MANUFACTURERS
TABLE 30 DISPOSABLES: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.3 DEVICES
TABLE 31 DEVICES: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 32 DEVICES: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.3.1 CENTRIFUGAL DEVICES
6.3.1.1 Increasing installation in hospitals to drive market
TABLE 33 CENTRIFUGAL DEVICES AVAILABLE
TABLE 34 CENTRIFUGAL DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.3.2 MEMBRANE SEPARATORS
6.3.2.1 Difficulty in separating large volumes of plasma to limit market
TABLE 35 MEMBRANE SEPARATORS AVAILABLE
TABLE 36 MEMBRANE SEPARATORS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
7 LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION
7.1 INTRODUCTION
TABLE 37 LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
7.2 RESEARCH APPLICATIONS
7.2.1 GROWING NUMBER OF CLINICAL TRIALS TO DRIVE SEGMENT
TABLE 38 COMPANIES DEVELOPING FDA-APPROVED CAR-T CELL THERAPIES
TABLE 39 RESEARCH APPLICATIONS: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
7.3 THERAPEUTIC APPLICATIONS
7.3.1 RISING ADOPTION OF LEUKAPHERESIS FOR LEUKEMIA TREATMENT TO FUEL MARKET
TABLE 40 THERAPEUTIC APPLICATIONS: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
8 LEUKAPHERESIS PRODUCTS MARKET, BY END USER
8.1 INTRODUCTION
TABLE 41 LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)
8.2 BLOOD COMPONENT PROVIDERS & BLOOD CENTERS
8.2.1 INCREASING BLOOD DONATION TO DRIVE MARKET
TABLE 42 BLOOD COMPONENT PROVIDERS & BLOOD CENTERS: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
8.3 ACADEMIC & RESEARCH INSTITUTES
8.3.1 COLLABORATIONS WITH PHARMACEUTICAL COMPANIES TO BOOST MARKET
TABLE 43 ACADEMIC & RESEARCH INSTITUTES: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
8.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
8.4.1 INCREASING NUMBER OF CLINICAL TRIALS TO DRIVE SEGMENT
TABLE 44 PHARMA-BIOTECH COMPANIES DEVELOPING CAR-T CELL TECHNOLOGIES
TABLE 45 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
8.5 HOSPITALS & TRANSFUSION CENTERS
8.5.1 GROWING NEED FOR TRANSFUSIONS TO PROPEL MARKET
TABLE 46 HOSPITALS & TRANSFUSION CENTERS: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
9 LEUKOPAKS MARKET, BY TYPE
9.1 INTRODUCTION
TABLE 47 LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 48 LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
9.2 MOBILIZED LEUKOPAKS
9.2.1 INCREASING USE IN CLINICAL RESEARCH TO DRIVE MARKET
TABLE 49 TREATMENT REGIMENS FOR DEVELOPMENT OF MOBILIZED LEUKOPAKS
TABLE 50 MOBILIZED LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 51 MOBILIZED LEUKOPAKS MARKET, BY REGION, 2021–2028 (UNITS)
9.3 NON-MOBILIZED LEUKOPAKS
9.3.1 LOW COST TO PROPEL MARKET
TABLE 52 NUMBER OF CELLS IN NON-MOBILIZED LEUKOPAKS
TABLE 53 COMPARATIVE ANALYSIS OF MOBILIZED AND NON-MOBILIZED LEUKOPAKS
TABLE 54 COMPOSITION OF MOBILIZED AND NON-MOBILIZED LEUKOPAKS
TABLE 55 NON-MOBILIZED LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 56 NON-MOBILIZED LEUKOPAKS MARKET, BY REGION, 2021–2028 (UNITS)
9.4 DISEASED LEUKOPAKS
9.4.1 RISING USE FOR CELL INTERACTION AND DRUG TOXICITY STUDIES TO BOOST MARKET
TABLE 57 DISEASED LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 58 DISEASED LEUKOPAKS MARKET, BY REGION, 2021–2028 (UNITS)
9.5 ISOLATED PBMCS
9.5.1 INCREASING RESEARCH FOCUS ON CELL-BASED THERAPIES TO FUEL MARKET
TABLE 59 IMMUNE CELL TYPES AND TARGETED DISEASES
TABLE 60 ISOLATED PBMCS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 61 ISOLATED PBMCS MARKET, BY REGION, 2021–2028 (UNITS)
10 LEUKOPAKS MARKET, BY INDICATION
10.1 INTRODUCTION
FIGURE 57 NUMBER OF GLOBAL CLINICAL TRIALS WITH CHIMERIC ANTIGEN RECEPTOR (CAR) CELLS
TABLE 62 LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
10.2 ACUTE LYMPHOCYTIC LEUKEMIA
10.2.1 RISING INCIDENCE OF DISEASE TO DRIVE MARKET
TABLE 63 ACUTE LYMPHOCYTIC LEUKEMIA: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
10.3 MULTIPLE MYELOMA
10.3.1 RISING DIAGNOSIS RATE TO FUEL SEGMENT
FIGURE 58 INCIDENCE OF MULTIPLE MYELOMA IN 2020
TABLE 64 MULTIPLE MYELOMA: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
10.4 NON-HODGKIN’S LYMPHOMA
10.4.1 DEVELOPMENT OF NOVEL THERAPIES TO BOOST MARKET
TABLE 65 NON-HODGKIN’S LYMPHOMA: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
10.5 CHRONIC LYMPHOCYTIC LEUKEMIA
10.5.1 RISING NUMBER OF CASES TO PROPEL MARKET
TABLE 66 CHRONIC LYMPHOCYTIC LEUKEMIA: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
10.6 PANCREATIC CANCER
10.6.1 DEVELOPMENT OF NEW DIAGNOSTIC TECHNIQUES TO DRIVE SEGMENT
FIGURE 59 INCIDENCE OF PANCREATIC CANCER IN 2020
TABLE 67 PANCREATIC CANCER: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
10.7 HEPATOCELLULAR CARCINOMA
10.7.1 INCREASING INCIDENCE OF VIRAL HEPATITIS TO FUEL SEGMENT
TABLE 68 HEPATOCELLULAR CARCINOMA: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
10.8 OTHER INDICATIONS
TABLE 69 OTHER INDICATIONS: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
11 LEUKOPAKS MARKET, BY END USER
11.1 INTRODUCTION
TABLE 70 LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.2 ACADEMIC & RESEARCH INSTITUTES
11.2.1 INCREASING INDUSTRY?ACADEMIC RESEARCH PARTNERSHIPS TO DRIVE MARKET
TABLE 71 ACADEMIC & RESEARCH INSTITUTES: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
11.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
11.3.1 RISING DEMAND FOR TARGET DRUG DEVELOPMENT TO PROPEL MARKET
FIGURE 60 PERCENTAGE OF GLOBAL CAR-T DRUGS IN US AND CHINA, BY YEAR OF FIRST IDENTIFICATION/REPORT
TABLE 72 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
11.4 CONTRACT RESEARCH ORGANIZATIONS
11.4.1 INCREASING CLINICAL TRIAL SPONSORSHIP TO DRIVE MARKET
TABLE 73 CONTRACT RESEARCH ORGANIZATIONS: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
12 LEUKAPHERESIS MARKET, BY REGION
12.1 INTRODUCTION
FIGURE 61 LEUKAPHERESIS PRODUCTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
TABLE 74 LEUKAPHERESIS PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION)
FIGURE 62 LEUKOPAKS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
TABLE 75 LEUKOPAKS MARKET, BY REGION, 2021–2028 (USD MILLION)
12.2 NORTH AMERICA
12.2.1 RECESSION IMPACT: NORTH AMERICA
FIGURE 63 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET SNAPSHOT
TABLE 76 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 77 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 78 NORTH AMERICA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 79 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 80 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 81 NORTH AMERICA: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 82 NORTH AMERICA: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 83 NORTH AMERICA: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 84 NORTH AMERICA: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.2.2 US
12.2.2.1 Presence of leading pharmaceutical and biotechnology companies to drive market
TABLE 85 DIAGNOSIS-RELATED GROUP REIMBURSEMENT (DRG)
TABLE 86 US: KEY MACROINDICATORS
TABLE 87 US: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 88 US: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 89 US: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 90 US: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 91 US: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 92 US: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 93 US: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.2.3 CANADA
12.2.3.1 Rising prevalence of blood cancer to stimulate market growth
TABLE 94 CANADA: KEY MACROINDICATORS
TABLE 95 CANADA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 96 CANADA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 97 CANADA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 98 CANADA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 99 CANADA: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 100 CANADA: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 101 CANADA: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3 EUROPE
12.3.1 RECESSION IMPACT: EUROPE
FIGURE 64 EUROPE: LEUKAPHERESIS PRODUCTS MARKET SNAPSHOT
TABLE 102 EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 103 EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 104 EUROPE: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 105 EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 106 EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 107 EUROPE: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 108 EUROPE: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 109 EUROPE: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 110 EUROPE: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3.2 UK
12.3.2.1 Rising awareness of cell-based therapies to propel market
TABLE 111 UK: KEY MACROINDICATORS
TABLE 112 UK: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 113 UK: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 114 UK: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 115 UK: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 116 UK: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 117 UK: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 118 UK: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3.3 GERMANY
12.3.3.1 Increasing research on cancer immunotherapies to boost market
TABLE 119 GERMANY: KEY MACROINDICATORS
TABLE 120 GERMANY: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 121 GERMANY: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 122 GERMANY: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 123 GERMANY: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 124 GERMANY: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 125 GERMANY: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 126 GERMANY: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3.4 SPAIN
12.3.4.1 Rising focus on development of novel CAR-T cell therapies to fuel market
TABLE 127 SPAIN: KEY MACROINDICATORS
TABLE 128 SPAIN: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 129 SPAIN: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 130 SPAIN: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 131 SPAIN: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 132 SPAIN: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 133 SPAIN: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 134 SPAIN: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3.5 FRANCE
12.3.5.1 Government healthcare initiatives to drive market
TABLE 135 FRANCE: KEY MACROINDICATORS
TABLE 136 FRANCE: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 137 FRANCE: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 138 FRANCE: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 139 FRANCE: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 140 FRANCE: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 141 FRANCE: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 142 FRANCE: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3.6 ITALY
12.3.6.1 Increasing adoption of cell-based therapies to boost market
TABLE 143 ITALY: COMMERCIAL CAR-T CELL THERAPIES APPROVED BY EMA (2022)
TABLE 144 ITALY: KEY MACROINDICATORS
TABLE 145 ITALY: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 146 ITALY: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 147 ITALY: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 148 ITALY: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 149 ITALY: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 150 ITALY: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 151 ITALY: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3.7 REST OF EUROPE
TABLE 152 REST OF EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 153 REST OF EUROPE: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 154 REST OF EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 155 REST OF EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 156 REST OF EUROPE: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 157 REST OF EUROPE: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 158 REST OF EUROPE: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.4 ASIA PACIFIC
12.4.1 RECESSION IMPACT: ASIA PACIFIC
FIGURE 65 ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET SNAPSHOT
TABLE 159 ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 160 ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 161 ASIA PACIFIC: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 162 ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 163 ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 164 ASIA PACIFIC: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 165 ASIA PACIFIC: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 166 ASIA PACIFIC: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 167 ASIA PACIFIC: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.4.2 CHINA
12.4.2.1 Growing awareness of benefits of leukapheresis to drive market
FIGURE 66 CHINA: NUMBER OF CAR-T BASED CLINICAL TRIALS REGISTERED (2013–2020)
TABLE 168 CHINA: KEY MACROINDICATORS
TABLE 169 CHINA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 170 CHINA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 171 CHINA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 172 CHINA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 173 CHINA: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 174 CHINA: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 175 CHINA: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.4.3 JAPAN
12.4.3.1 Focus on development of cell therapies to boost market
TABLE 176 JAPAN: KEY MACROINDICATORS
TABLE 177 JAPAN: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 178 JAPAN: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 179 JAPAN: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 180 JAPAN: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 181 JAPAN: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 182 JAPAN: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 183 JAPAN: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.4.4 INDIA
12.4.4.1 Rising government investment in healthcare to drive market growth
TABLE 184 INDIA: KEY MACROINDICATORS
TABLE 185 INDIA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 186 INDIA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 187 INDIA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 188 INDIA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 189 INDIA: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 190 INDIA: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 191 INDIA: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.4.5 AUSTRALIA
12.4.5.1 Increasing incidence of blood cancer to drive market
TABLE 192 AUSTRALIA: KEY MACROINDICATORS
TABLE 193 AUSTRALIA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 194 AUSTRALIA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 195 AUSTRALIA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 196 AUSTRALIA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 197 AUSTRALIA: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 198 AUSTRALIA: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 199 AUSTRALIA: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.4.6 SOUTH KOREA
12.4.6.1 Increasing research in cell therapy to fuel market growth
TABLE 200 SOUTH KOREA: KEY MACROINDICATORS
TABLE 201 SOUTH KOREA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 202 SOUTH KOREA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 203 SOUTH KOREA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 204 SOUTH KOREA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 205 SOUTH KOREA: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 206 SOUTH KOREA: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 207 SOUTH KOREA: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.4.7 REST OF ASIA PACIFIC
TABLE 208 REST OF ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 209 REST OF ASIA PACIFIC: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 210 REST OF ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 211 REST OF ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 212 REST OF ASIA PACIFIC: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 213 REST OF ASIA PACIFIC: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 214 REST OF ASIA PACIFIC: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.5 LATIN AMERICA
12.5.1 RECESSION IMPACT: LATIN AMERICA
TABLE 215 LATIN AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 216 LATIN AMERICA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 217 LATIN AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 218 LATIN AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 219 LATIN AMERICA: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 220 LATIN AMERICA: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 221 LATIN AMERICA: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.6 MIDDLE EAST & AFRICA
12.6.1 RECESSION IMPACT: MIDDLE EAST & AFRICA
TABLE 222 MIDDLE EAST & AFRICA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 223 MIDDLE EAST & AFRICA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 224 MIDDLE EAST & AFRICA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 225 MIDDLE EAST & AFRICA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 226 MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 227 MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 228 MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)
13 COMPETITIVE LANDSCAPE
13.1 INTRODUCTION
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN LEUKAPHERESIS PRODUCTS MARKET
13.2.2 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN LEUKOPAKS MARKET
13.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 67 LEUKAPHERESIS MARKET: REVENUE SHARE ANALYSIS OF TOP FOUR MARKET PLAYERS
13.4 COMPETITIVE BENCHMARKING (LEUKAPHERESIS PRODUCTS MARKET)
TABLE 229 OVERALL COMPANY FOOTPRINT
TABLE 230 COMPANY END USER FOOTPRINT
TABLE 231 COMPANY APPLICATION FOOTPRINT
TABLE 232 COMPANY REGION FOOTPRINT
13.5 MARKET SHARE ANALYSIS (LEUKAPHERESIS PRODUCTS, 2022)
TABLE 233 LEUKAPHERESIS PRODUCTS MARKET: DEGREE OF COMPETITION
FIGURE 68 LEUKAPHERESIS PRODUCTS MARKET SHARE, BY KEY PLAYER (2022)
13.6 MARKET SHARE ANALYSIS (LEUKOPAKS, 2022)
TABLE 234 LEUKOPAKS MARKET: DEGREE OF COMPETITION
FIGURE 69 LEUKOPAKS MARKET SHARE, BY KEY PLAYER (2022)
13.7 COMPANY EVALUATION MATRIX, 2022 (LEUKAPHERESIS PRODUCTS MARKET)
13.7.1 STARS
13.7.2 EMERGING LEADERS
13.7.3 PERVASIVE PLAYERS
13.7.4 PARTICIPANTS
FIGURE 70 LEUKAPHERESIS PRODUCTS MARKET: COMPANY EVALUATION MATRIX (2022)
13.8 COMPETITIVE EVALUATION MATRIX FOR START-UPS/SMES (LEUKAPHERESIS MARKET) (2022)
TABLE 235 LEUKAPHERESIS MARKET: KEY START-UPS/SMES
13.8.1 PROGRESSIVE COMPANIES
13.8.2 DYNAMIC COMPANIES
13.8.3 STARTING BLOCKS
13.8.4 RESPONSIVE COMPANIES
FIGURE 71 LEUKAPHERESIS MARKET: SMES/START-UPS COMPANY EVALUATION QUADRANT (2022)
13.9 COMPETITIVE EVALUATION MATRIX, 2022 (LEUKOPAKS MARKET)
13.9.1 STARS
13.9.2 EMERGING LEADERS
13.9.3 PERVASIVE PLAYERS
13.9.4 PARTICIPANTS
FIGURE 72 LEUKOPAKS MARKET: COMPANY EVALUATION MATRIX (2022)
13.10 COMPETITIVE SCENARIO AND TRENDS
TABLE 236 PRODUCT LAUNCHES AND APPROVALS (JANUARY 2019–AUGUST 2023)
TABLE 237 DEALS (JANUARY 2019–AUGUST 2023)
TABLE 238 OTHER DEVELOPMENTS (JANUARY 2019–AUGUST 2023)
14 COMPANY PROFILES
14.1 KEY PLAYERS (LEUKAPHERESIS PRODUCTS MARKET)
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
14.1.1 TERUMO BCT
TABLE 239 TERUMO BCT: COMPANY OVERVIEW
FIGURE 73 TERUMO BCT: COMPANY SNAPSHOT (2022)
14.1.2 FRESENIUS SE & CO. KGAA
TABLE 240 FRESENIUS SE & CO. KGAA: COMPANY OVERVIEW
FIGURE 74 FRESENIUS SE & CO. KGAA: COMPANY SNAPSHOT (2022)
14.1.3 HAEMONETICS CORPORATION
TABLE 241 HAEMONETICS CORPORATION: COMPANY OVERVIEW
FIGURE 75 HAEMONETICS CORPORATION: COMPANY SNAPSHOT (2022)
14.1.4 ASAHI KASEI CORPORATION
TABLE 242 ASAHI KASEI CORPORATION: COMPANY OVERVIEW
FIGURE 76 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2022)
14.1.5 MACOPHARMA SA
TABLE 243 MACOPHARMA SA: COMPANY OVERVIEW
14.1.6 MILTENYI BIOTEC
TABLE 244 MILTENYI BIOTEC: COMPANY OVERVIEW
14.2 OTHER PLAYERS (LEUKAPHERESIS PRODUCTS MARKET)
14.2.1 GUANGZHOU DAJI MEDICAL SCIENCE AND TECHNOLOGY CO. LTD.
TABLE 245 GUANGZHOU DAJI MEDICAL SCIENCE AND TECHNOLOGY CO. LTD.: COMPANY OVERVIEW
14.2.2 MEDICA SPA.
TABLE 246 MEDICA SPA: COMPANY OVERVIEW
14.2.3 PURIBLOOD MEDICAL CO. LTD.
TABLE 247 PURIBLOOD MEDICAL CO. LTD.: COMPANY OVERVIEW
14.2.4 BEIJING ZKSK TECHNOLOGY CO. LTD.
TABLE 248 BEIJING ZKSK TECHNOLOGY CO. LTD.: COMPANY OVERVIEW
14.2.5 SB-KAWASUMI LABORATORIES, INC.
TABLE 249 SB-KAWASUMI LABORATORIES, INC.: COMPANY OVERVIEW
14.2.6 NIKKISO CO., LTD.
TABLE 250 NIKKISO CO., LTD.: COMPANY OVERVIEW
FIGURE 77 NIKKISO CO., LTD.: COMPANY SNAPSHOT (2022)
14.2.7 PALL CORPORATION
TABLE 251 PALL CORPORATION: COMPANY OVERVIEW
14.3 KEY PLAYERS (LEUKOPAKS MARKET)
14.3.1 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
TABLE 252 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY OVERVIEW
FIGURE 78 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT (2022)
14.3.2 DISCOVERY LIFE SCIENCES, INC.
TABLE 253 DISCOVERY LIFE SCIENCES, INC.: COMPANY OVERVIEW
14.3.3 BIOIVT
TABLE 254 BIOIVT: COMPANY OVERVIEW
14.3.4 PRECISION FOR MEDICINE, INC.
TABLE 255 PRECISION FOR MEDICINE, INC.: COMPANY OVERVIEW
14.3.5 STEMEXPRESS, LLC
TABLE 256 STEMEXPRESS, LLC: COMPANY OVERVIEW
14.4 OTHER PLAYERS (LEUKOPAKS MARKET)
14.4.1 LONZA GROUP AG
TABLE 257 LONZA GROUP AG: COMPANY OVERVIEW
FIGURE 79 LONZA GROUP AG: COMPANY SNAPSHOT (2022)
14.4.2 CALTAG MEDSYSTEMS LIMITED
TABLE 258 CALTAG MEDSYSTEMS LIMITED: COMPANY OVERVIEW
14.4.3 ZENBIO, INC.
TABLE 259 ZENBIO, INC.: COMPANY OVERVIEW
14.4.4 STEMCELL TECHNOLOGIES
14.4.5 TRINA BIOREACTIVES AG
14.4.6 ACCEGEN
14.4.7 FIRST CHOICE BIO LLC
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
15 APPENDIX
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
15.3 CUSTOMIZATION OPTIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 TYPE
1.2.2 APPLICATION
1.2.3 END USER
1.2.4 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
TABLE 1 STANDARD CURRENCY CONVERSION RATES
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
1.7 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Insights from primary experts
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS (LEUKAPHERESIS PRODUCTS AND LEUKOPAKS MARKET)
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION (LEUKAPHERESIS PRODUCTS MARKET)
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, AND REGION (LEUKAPHERESIS PRODUCTS MARKET)
FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION (LEUKOPAKS MARKET)
FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, AND REGION (LEUKOPAKS MARKET)
2.2 MARKET SIZE ESTIMATION: LEUKAPHERESIS PRODUCTS MARKET
FIGURE 8 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 9 REVENUE SHARE ANALYSIS ILLUSTRATION: TERUMO CORPORATION (2022)
FIGURE 10 REVENUE ANALYSIS OF TOP FOUR COMPANIES: LEUKAPHERESIS PRODUCTS MARKET (2022)
FIGURE 11 DEMAND-SIDE APPROACH: LEUKAPHERESIS PRODUCTS MARKET (2022)
FIGURE 12 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2023–2028)
FIGURE 13 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS (LEUKAPHERESIS PRODUCTS MARKET)
FIGURE 14 TOP-DOWN APPROACH
2.3 MARKET SIZE ESTIMATION: LEUKOPAKS MARKET
FIGURE 15 VOLUME ESTIMATION OF LEUKOPAKS MARKET
FIGURE 16 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS (LEUKOPAKS MARKET)
FIGURE 17 TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 18 MARKET DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE ANALYSIS
2.6 RESEARCH ASSUMPTIONS
2.7 RISK ASSESSMENT
TABLE 2 RISK ASSESSMENT: LEUKAPHERESIS PRODUCTS AND LEUKOPAKS MARKETS
2.8 METHODOLOGY-RELATED LIMITATIONS
2.9 RECESSION IMPACT ANALYSIS
3 EXECUTIVE SUMMARY
FIGURE 19 LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 20 LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 21 LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 22 LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 23 LEUKOPAKS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 24 LEUKOPAKS MARKET, BY INDICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 25 LEUKOPAKS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 26 GEOGRAPHIC SNAPSHOT: LEUKAPHERESIS PRODUCTS MARKET
FIGURE 27 GEOGRAPHIC SNAPSHOT: LEUKOPAKS MARKET
4 PREMIUM INSIGHTS
4.1 LEUKAPHERESIS PRODUCTS MARKET: OVERVIEW
FIGURE 28 INCREASING INCIDENCE AND PREVALENCE OF LEUKEMIA TO DRIVE MARKET
4.2 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE AND COUNTRY
FIGURE 29 DISPOSABLES TO DOMINATE NORTH AMERICAN LEUKAPHERESIS PRODUCTS MARKET IN 2022
4.3 LEUKAPHERESIS PRODUCTS MARKET: GEOGRAPHIC MIX
FIGURE 30 CHINA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
4.4 LEUKAPHERESIS PRODUCTS MARKET: REGIONAL MIX
FIGURE 31 NORTH AMERICA DOMINATED MARKET IN 2022
4.5 LEUKOPAKS MARKET: OVERVIEW
FIGURE 32 RISING DEMAND FOR LEUKOPAKS FOR USE IN RESEARCH APPLICATIONS TO DRIVE MARKET
4.6 NORTH AMERICA: LEUKOPAKS MARKET, BY PRODUCT AND COUNTRY
FIGURE 33 MOBILIZED LEUKOPAKS COMMANDED LARGEST SHARE OF MARKET IN 2022
4.7 LEUKOPAKS MARKET: GEOGRAPHIC MIX
FIGURE 34 CHINA TO RECORD HIGHEST GROWTH DURING FORECAST PERIOD
4.8 LEUKOPAKS MARKET: REGIONAL MIX
FIGURE 35 ASIA PACIFIC MARKET TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 36 LEUKAPHERESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising incidence and prevalence of leukemia
FIGURE 37 ESTIMATED NUMBER OF NEW LEUKEMIA CASES, BY REGION (2020–2040)
FIGURE 38 ESTIMATED NUMBER OF LEUKEMIA DEATHS, BY REGION (2020–2040)
5.2.1.2 Increasing blood donation
5.2.1.3 Growing demand for leukopaks in clinical research
FIGURE 39 GROWTH IN NUMBER OF CAR-T CLINICAL TRIALS, 2009–2020
FIGURE 40 NUMBER OF CAR-T THERAPY CLINICAL TRIALS: US VS. CHINA, 2022
5.2.2 RESTRAINTS
5.2.2.1 High cost of therapeutic leukapheresis and leukopaks
TABLE 3 COST OF LEUKOPAKS, BY TYPE
5.2.2.2 Stringent donor recruitment criteria
TABLE 4 DONOR SELECTION CRITERIA
TABLE 5 FREQUENCY OF BLOOD DONATION FROM HEALTHY DONORS
5.2.2.3 Dearth of skilled professionals
5.2.2.4 Complications associated with therapeutic leukapheresis
5.2.2.5 Long duration of procedure
5.2.2.6 High cost of cellular immunotherapies and lack of favorable reimbursement
5.2.3 OPPORTUNITIES
5.2.3.1 Growing focus on leukapheresis for pediatric patients
5.2.3.2 Increasing investments in CAR-T therapies in emerging economies
5.2.3.3 Gaps in current leukapheresis technologies
5.2.4 CHALLENGES
5.2.4.1 Concerns related to safety of blood transfusion in emerging economies
5.3 PORTER’S FIVE FORCES ANALYSIS
FIGURE 41 PORTER’S FIVE FORCES ANALYSIS: LEUKAPHERESIS MARKET
TABLE 6 LEUKAPHERESIS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.3.1 THREAT FROM NEW ENTRANTS
5.3.2 THREAT FROM SUBSTITUTES
5.3.3 BARGAINING POWER OF SUPPLIERS
5.3.4 BARGAINING POWER OF BUYERS
5.3.5 INTENSITY OF COMPETITIVE RIVALRY
5.4 INDUSTRY TRENDS
5.4.1 INCREASING COLLABORATIONS BETWEEN PHARMA AND BIOTECH COMPANIES
TABLE 7 RECENT DEVELOPMENTS RELATED TO CAR-T THERAPY
5.4.2 INTRODUCTION OF CUSTOMIZABLE CRYOPRESERVED LEUKOPAKS
5.5 TECHNOLOGY ANALYSIS
5.5.1 KEY TECHNOLOGIES
5.5.1.1 Centrifugal-based leukapheresis
5.5.1.2 Membrane-based leukapheresis
TABLE 8 MATERIALS USED FOR LEUKOCYTE FILTRATION AND SURFACE MODIFICATION TECHNIQUES APPLIED FOR ENHANCED SEPARATION
5.5.2 EMERGING TECHNOLOGIES
5.5.2.1 Adsorption-based leukapheresis
5.5.2.2 Microfluidic devices for leukapheresis
5.5.2.3 Integration of AI in leukapheresis treatment
5.6 PRICING ANALYSIS (LEUKOPAKS MARKET)
TABLE 9 ASP OF NON-MOBILIZED LEUKOPAKS
TABLE 10 ASP OF MOBILIZED LEUKOPAKS
TABLE 11 ASP OF MOBILIZED ISOLATED CELLS
5.7 KEY CONFERENCES AND EVENTS, 2023–2024
TABLE 12 LEUKAPHERESIS MARKET: CONFERENCES AND EVENTS
5.8 REGULATORY ANALYSIS (LEUKAPHERESIS PRODUCTS MARKET)
5.8.1 NORTH AMERICA
5.8.1.1 US
5.8.1.2 Canada
5.8.2 EUROPE
5.8.3 ASIA PACIFIC
5.8.3.1 Japan
5.8.3.2 China
5.9 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 17 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.10 REGULATORY ANALYSIS (LEUKOPAKS MARKET)
5.10.1 US
TABLE 18 LIST OF FDA-APPROVED CAR-T THERAPEUTICS
5.10.2 EUROPE
5.10.3 JAPAN
5.10.4 INDIA
5.11 VALUE CHAIN ANALYSIS
FIGURE 42 VALUE CHAIN: LEUKAPHERESIS MARKET (LEUKAPHERESIS SYSTEMS)
5.12 SUPPLY CHAIN ANALYSIS
FIGURE 43 LEUKAPHERESIS MARKET: STAKEHOLDERS IN SUPPLY CHAIN
5.13 ECOSYSTEM ANALYSIS
FIGURE 44 LEUKAPHERESIS MARKET: ECOSYSTEM MAP
TABLE 19 LEUKAPHERESIS MARKET: ECOSYSTEM
5.14 HS CODES: CENTRIFUGAL DEVICES AND MEMBRANE SEPARATORS
5.15 PATENT ANALYSIS
5.15.1 PATENT PUBLICATION TRENDS IN LEUKAPHERESIS PRODUCTS MARKET
FIGURE 45 GLOBAL PATENT PUBLICATION TRENDS IN LEUKAPHERESIS PRODUCTS MARKET, JANUARY 2019–AUGUST 2023
5.15.2 PATENT PUBLICATION TRENDS IN LEUKOPAKS MARKET
FIGURE 46 GLOBAL PATENT PUBLICATION TRENDS IN LEUKOPAKS MARKET, JANUARY 2019–AUGUST 2023
5.15.3 TOP APPLICANTS FOR LEUKAPHERESIS PRODUCT PATENTS
FIGURE 47 TOP APPLICANTS FOR LEUKAPHERESIS PRODUCT PATENTS, JANUARY 2019–AUGUST 2023
5.15.4 TOP APPLICANTS FOR LEUKOPAK PATENTS
FIGURE 48 TOP APPLICANTS FOR LEUKOPAK PATENTS, JANUARY 2019–AUGUST 2023
5.15.5 JURISDICTION ANALYSIS: TOP COUNTRIES FOR LEUKAPHERESIS MARKET PATENTS
FIGURE 49 JURISDICTION ANALYSIS: TOP COUNTRIES FOR LEUKAPHERESIS PATENTS, JANUARY 2019–AUGUST 2023
FIGURE 50 JURISDICTION ANALYSIS: TOP COUNTRIES FOR LEUKOPAK PATENTS, JANUARY 2019–AUGUST 2023
5.15.6 TOP PATENT APPLICANTS/OWNERS
FIGURE 51 TOP APPLICANTS AND OWNERS FOR LEUKAPHERESIS PRODUCT PATENTS, JANUARY 2019–AUGUST 2023
FIGURE 52 TOP APPLICANTS AND OWNERS FOR LEUKOPAK PATENTS, JANUARY 2019–AUGUST 2023
TABLE 20 LEUKAPHERESIS PRODUCTS MARKET: MAJOR PATENTS (2020–2022)
TABLE 21 LEUKOPAKS MARKET: MAJOR PATENTS (2019–2022)
5.16 KEY STAKEHOLDERS AND BUYING CRITERIA
5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 53 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR LEUKAPHERESIS PRODUCTS AND LEUKOPAKS
TABLE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR LEUKAPHERESIS PRODUCTS AND LEUKOPAKS
5.16.2 BUYING CRITERIA
FIGURE 54 KEY BUYING CRITERIA FOR LEUKAPHERESIS PRODUCTS AND LEUKOPAKS
TABLE 23 KEY BUYING CRITERIA FOR LEUKAPHERESIS PRODUCTS AND LEUKOPAKS
5.17 CASE STUDIES
TABLE 24 CASE STUDY 1: ESTIMATING MARKET SIZE OF LEUKAPHERESIS PRODUCTS AND MARKET SHARE ANALYSIS FOR KEY PRODUCTS AT COUNTRY LEVEL
TABLE 25 CASE STUDY 2: ESTIMATING MARKET SIZE OF LEUKOPAKS AND MARKET SHARE ANALYSIS FOR KEY PRODUCTS AT COUNTRY LEVEL
5.18 ADJACENT MARKET ANALYSIS
5.18.1 PLASMA FRACTIONATION MARKET
FIGURE 55 PLASMA FRACTIONATION MARKET OVERVIEW
5.18.2 APHERESIS MARKET
FIGURE 56 APHERESIS MARKET OVERVIEW
6 LEUKAPHERESIS PRODUCTS MARKET, BY TYPE
6.1 INTRODUCTION
TABLE 26 LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 27 LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.2 DISPOSABLES
6.2.1 RECURRENT DEMAND TO BOOST SEGMENT
TABLE 28 LEUKOREDUCTION FILTER MANUFACTURERS
TABLE 29 LEUKAPHERESIS COLUMN AND CELL SEPARATOR MANUFACTURERS
TABLE 30 DISPOSABLES: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.3 DEVICES
TABLE 31 DEVICES: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 32 DEVICES: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.3.1 CENTRIFUGAL DEVICES
6.3.1.1 Increasing installation in hospitals to drive market
TABLE 33 CENTRIFUGAL DEVICES AVAILABLE
TABLE 34 CENTRIFUGAL DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.3.2 MEMBRANE SEPARATORS
6.3.2.1 Difficulty in separating large volumes of plasma to limit market
TABLE 35 MEMBRANE SEPARATORS AVAILABLE
TABLE 36 MEMBRANE SEPARATORS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
7 LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION
7.1 INTRODUCTION
TABLE 37 LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
7.2 RESEARCH APPLICATIONS
7.2.1 GROWING NUMBER OF CLINICAL TRIALS TO DRIVE SEGMENT
TABLE 38 COMPANIES DEVELOPING FDA-APPROVED CAR-T CELL THERAPIES
TABLE 39 RESEARCH APPLICATIONS: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
7.3 THERAPEUTIC APPLICATIONS
7.3.1 RISING ADOPTION OF LEUKAPHERESIS FOR LEUKEMIA TREATMENT TO FUEL MARKET
TABLE 40 THERAPEUTIC APPLICATIONS: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
8 LEUKAPHERESIS PRODUCTS MARKET, BY END USER
8.1 INTRODUCTION
TABLE 41 LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)
8.2 BLOOD COMPONENT PROVIDERS & BLOOD CENTERS
8.2.1 INCREASING BLOOD DONATION TO DRIVE MARKET
TABLE 42 BLOOD COMPONENT PROVIDERS & BLOOD CENTERS: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
8.3 ACADEMIC & RESEARCH INSTITUTES
8.3.1 COLLABORATIONS WITH PHARMACEUTICAL COMPANIES TO BOOST MARKET
TABLE 43 ACADEMIC & RESEARCH INSTITUTES: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
8.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
8.4.1 INCREASING NUMBER OF CLINICAL TRIALS TO DRIVE SEGMENT
TABLE 44 PHARMA-BIOTECH COMPANIES DEVELOPING CAR-T CELL TECHNOLOGIES
TABLE 45 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
8.5 HOSPITALS & TRANSFUSION CENTERS
8.5.1 GROWING NEED FOR TRANSFUSIONS TO PROPEL MARKET
TABLE 46 HOSPITALS & TRANSFUSION CENTERS: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
9 LEUKOPAKS MARKET, BY TYPE
9.1 INTRODUCTION
TABLE 47 LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 48 LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
9.2 MOBILIZED LEUKOPAKS
9.2.1 INCREASING USE IN CLINICAL RESEARCH TO DRIVE MARKET
TABLE 49 TREATMENT REGIMENS FOR DEVELOPMENT OF MOBILIZED LEUKOPAKS
TABLE 50 MOBILIZED LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 51 MOBILIZED LEUKOPAKS MARKET, BY REGION, 2021–2028 (UNITS)
9.3 NON-MOBILIZED LEUKOPAKS
9.3.1 LOW COST TO PROPEL MARKET
TABLE 52 NUMBER OF CELLS IN NON-MOBILIZED LEUKOPAKS
TABLE 53 COMPARATIVE ANALYSIS OF MOBILIZED AND NON-MOBILIZED LEUKOPAKS
TABLE 54 COMPOSITION OF MOBILIZED AND NON-MOBILIZED LEUKOPAKS
TABLE 55 NON-MOBILIZED LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 56 NON-MOBILIZED LEUKOPAKS MARKET, BY REGION, 2021–2028 (UNITS)
9.4 DISEASED LEUKOPAKS
9.4.1 RISING USE FOR CELL INTERACTION AND DRUG TOXICITY STUDIES TO BOOST MARKET
TABLE 57 DISEASED LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 58 DISEASED LEUKOPAKS MARKET, BY REGION, 2021–2028 (UNITS)
9.5 ISOLATED PBMCS
9.5.1 INCREASING RESEARCH FOCUS ON CELL-BASED THERAPIES TO FUEL MARKET
TABLE 59 IMMUNE CELL TYPES AND TARGETED DISEASES
TABLE 60 ISOLATED PBMCS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 61 ISOLATED PBMCS MARKET, BY REGION, 2021–2028 (UNITS)
10 LEUKOPAKS MARKET, BY INDICATION
10.1 INTRODUCTION
FIGURE 57 NUMBER OF GLOBAL CLINICAL TRIALS WITH CHIMERIC ANTIGEN RECEPTOR (CAR) CELLS
TABLE 62 LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
10.2 ACUTE LYMPHOCYTIC LEUKEMIA
10.2.1 RISING INCIDENCE OF DISEASE TO DRIVE MARKET
TABLE 63 ACUTE LYMPHOCYTIC LEUKEMIA: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
10.3 MULTIPLE MYELOMA
10.3.1 RISING DIAGNOSIS RATE TO FUEL SEGMENT
FIGURE 58 INCIDENCE OF MULTIPLE MYELOMA IN 2020
TABLE 64 MULTIPLE MYELOMA: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
10.4 NON-HODGKIN’S LYMPHOMA
10.4.1 DEVELOPMENT OF NOVEL THERAPIES TO BOOST MARKET
TABLE 65 NON-HODGKIN’S LYMPHOMA: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
10.5 CHRONIC LYMPHOCYTIC LEUKEMIA
10.5.1 RISING NUMBER OF CASES TO PROPEL MARKET
TABLE 66 CHRONIC LYMPHOCYTIC LEUKEMIA: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
10.6 PANCREATIC CANCER
10.6.1 DEVELOPMENT OF NEW DIAGNOSTIC TECHNIQUES TO DRIVE SEGMENT
FIGURE 59 INCIDENCE OF PANCREATIC CANCER IN 2020
TABLE 67 PANCREATIC CANCER: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
10.7 HEPATOCELLULAR CARCINOMA
10.7.1 INCREASING INCIDENCE OF VIRAL HEPATITIS TO FUEL SEGMENT
TABLE 68 HEPATOCELLULAR CARCINOMA: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
10.8 OTHER INDICATIONS
TABLE 69 OTHER INDICATIONS: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
11 LEUKOPAKS MARKET, BY END USER
11.1 INTRODUCTION
TABLE 70 LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.2 ACADEMIC & RESEARCH INSTITUTES
11.2.1 INCREASING INDUSTRY?ACADEMIC RESEARCH PARTNERSHIPS TO DRIVE MARKET
TABLE 71 ACADEMIC & RESEARCH INSTITUTES: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
11.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
11.3.1 RISING DEMAND FOR TARGET DRUG DEVELOPMENT TO PROPEL MARKET
FIGURE 60 PERCENTAGE OF GLOBAL CAR-T DRUGS IN US AND CHINA, BY YEAR OF FIRST IDENTIFICATION/REPORT
TABLE 72 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
11.4 CONTRACT RESEARCH ORGANIZATIONS
11.4.1 INCREASING CLINICAL TRIAL SPONSORSHIP TO DRIVE MARKET
TABLE 73 CONTRACT RESEARCH ORGANIZATIONS: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
12 LEUKAPHERESIS MARKET, BY REGION
12.1 INTRODUCTION
FIGURE 61 LEUKAPHERESIS PRODUCTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
TABLE 74 LEUKAPHERESIS PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION)
FIGURE 62 LEUKOPAKS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
TABLE 75 LEUKOPAKS MARKET, BY REGION, 2021–2028 (USD MILLION)
12.2 NORTH AMERICA
12.2.1 RECESSION IMPACT: NORTH AMERICA
FIGURE 63 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET SNAPSHOT
TABLE 76 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 77 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 78 NORTH AMERICA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 79 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 80 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 81 NORTH AMERICA: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 82 NORTH AMERICA: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 83 NORTH AMERICA: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 84 NORTH AMERICA: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.2.2 US
12.2.2.1 Presence of leading pharmaceutical and biotechnology companies to drive market
TABLE 85 DIAGNOSIS-RELATED GROUP REIMBURSEMENT (DRG)
TABLE 86 US: KEY MACROINDICATORS
TABLE 87 US: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 88 US: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 89 US: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 90 US: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 91 US: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 92 US: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 93 US: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.2.3 CANADA
12.2.3.1 Rising prevalence of blood cancer to stimulate market growth
TABLE 94 CANADA: KEY MACROINDICATORS
TABLE 95 CANADA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 96 CANADA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 97 CANADA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 98 CANADA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 99 CANADA: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 100 CANADA: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 101 CANADA: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3 EUROPE
12.3.1 RECESSION IMPACT: EUROPE
FIGURE 64 EUROPE: LEUKAPHERESIS PRODUCTS MARKET SNAPSHOT
TABLE 102 EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 103 EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 104 EUROPE: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 105 EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 106 EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 107 EUROPE: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 108 EUROPE: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 109 EUROPE: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 110 EUROPE: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3.2 UK
12.3.2.1 Rising awareness of cell-based therapies to propel market
TABLE 111 UK: KEY MACROINDICATORS
TABLE 112 UK: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 113 UK: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 114 UK: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 115 UK: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 116 UK: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 117 UK: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 118 UK: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3.3 GERMANY
12.3.3.1 Increasing research on cancer immunotherapies to boost market
TABLE 119 GERMANY: KEY MACROINDICATORS
TABLE 120 GERMANY: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 121 GERMANY: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 122 GERMANY: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 123 GERMANY: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 124 GERMANY: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 125 GERMANY: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 126 GERMANY: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3.4 SPAIN
12.3.4.1 Rising focus on development of novel CAR-T cell therapies to fuel market
TABLE 127 SPAIN: KEY MACROINDICATORS
TABLE 128 SPAIN: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 129 SPAIN: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 130 SPAIN: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 131 SPAIN: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 132 SPAIN: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 133 SPAIN: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 134 SPAIN: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3.5 FRANCE
12.3.5.1 Government healthcare initiatives to drive market
TABLE 135 FRANCE: KEY MACROINDICATORS
TABLE 136 FRANCE: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 137 FRANCE: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 138 FRANCE: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 139 FRANCE: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 140 FRANCE: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 141 FRANCE: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 142 FRANCE: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3.6 ITALY
12.3.6.1 Increasing adoption of cell-based therapies to boost market
TABLE 143 ITALY: COMMERCIAL CAR-T CELL THERAPIES APPROVED BY EMA (2022)
TABLE 144 ITALY: KEY MACROINDICATORS
TABLE 145 ITALY: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 146 ITALY: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 147 ITALY: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 148 ITALY: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 149 ITALY: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 150 ITALY: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 151 ITALY: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3.7 REST OF EUROPE
TABLE 152 REST OF EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 153 REST OF EUROPE: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 154 REST OF EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 155 REST OF EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 156 REST OF EUROPE: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 157 REST OF EUROPE: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 158 REST OF EUROPE: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.4 ASIA PACIFIC
12.4.1 RECESSION IMPACT: ASIA PACIFIC
FIGURE 65 ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET SNAPSHOT
TABLE 159 ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 160 ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 161 ASIA PACIFIC: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 162 ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 163 ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 164 ASIA PACIFIC: LEUKOPAKS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 165 ASIA PACIFIC: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 166 ASIA PACIFIC: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 167 ASIA PACIFIC: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.4.2 CHINA
12.4.2.1 Growing awareness of benefits of leukapheresis to drive market
FIGURE 66 CHINA: NUMBER OF CAR-T BASED CLINICAL TRIALS REGISTERED (2013–2020)
TABLE 168 CHINA: KEY MACROINDICATORS
TABLE 169 CHINA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 170 CHINA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 171 CHINA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 172 CHINA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 173 CHINA: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 174 CHINA: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 175 CHINA: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.4.3 JAPAN
12.4.3.1 Focus on development of cell therapies to boost market
TABLE 176 JAPAN: KEY MACROINDICATORS
TABLE 177 JAPAN: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 178 JAPAN: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 179 JAPAN: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 180 JAPAN: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 181 JAPAN: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 182 JAPAN: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 183 JAPAN: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.4.4 INDIA
12.4.4.1 Rising government investment in healthcare to drive market growth
TABLE 184 INDIA: KEY MACROINDICATORS
TABLE 185 INDIA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 186 INDIA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 187 INDIA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 188 INDIA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 189 INDIA: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 190 INDIA: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 191 INDIA: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.4.5 AUSTRALIA
12.4.5.1 Increasing incidence of blood cancer to drive market
TABLE 192 AUSTRALIA: KEY MACROINDICATORS
TABLE 193 AUSTRALIA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 194 AUSTRALIA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 195 AUSTRALIA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 196 AUSTRALIA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 197 AUSTRALIA: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 198 AUSTRALIA: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 199 AUSTRALIA: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.4.6 SOUTH KOREA
12.4.6.1 Increasing research in cell therapy to fuel market growth
TABLE 200 SOUTH KOREA: KEY MACROINDICATORS
TABLE 201 SOUTH KOREA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 202 SOUTH KOREA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 203 SOUTH KOREA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 204 SOUTH KOREA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 205 SOUTH KOREA: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 206 SOUTH KOREA: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 207 SOUTH KOREA: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.4.7 REST OF ASIA PACIFIC
TABLE 208 REST OF ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 209 REST OF ASIA PACIFIC: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 210 REST OF ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 211 REST OF ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 212 REST OF ASIA PACIFIC: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 213 REST OF ASIA PACIFIC: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 214 REST OF ASIA PACIFIC: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.5 LATIN AMERICA
12.5.1 RECESSION IMPACT: LATIN AMERICA
TABLE 215 LATIN AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 216 LATIN AMERICA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 217 LATIN AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 218 LATIN AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 219 LATIN AMERICA: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 220 LATIN AMERICA: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 221 LATIN AMERICA: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.6 MIDDLE EAST & AFRICA
12.6.1 RECESSION IMPACT: MIDDLE EAST & AFRICA
TABLE 222 MIDDLE EAST & AFRICA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 223 MIDDLE EAST & AFRICA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 224 MIDDLE EAST & AFRICA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 225 MIDDLE EAST & AFRICA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 226 MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 227 MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 228 MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY END USER, 2021–2028 (USD MILLION)
13 COMPETITIVE LANDSCAPE
13.1 INTRODUCTION
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN LEUKAPHERESIS PRODUCTS MARKET
13.2.2 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN LEUKOPAKS MARKET
13.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 67 LEUKAPHERESIS MARKET: REVENUE SHARE ANALYSIS OF TOP FOUR MARKET PLAYERS
13.4 COMPETITIVE BENCHMARKING (LEUKAPHERESIS PRODUCTS MARKET)
TABLE 229 OVERALL COMPANY FOOTPRINT
TABLE 230 COMPANY END USER FOOTPRINT
TABLE 231 COMPANY APPLICATION FOOTPRINT
TABLE 232 COMPANY REGION FOOTPRINT
13.5 MARKET SHARE ANALYSIS (LEUKAPHERESIS PRODUCTS, 2022)
TABLE 233 LEUKAPHERESIS PRODUCTS MARKET: DEGREE OF COMPETITION
FIGURE 68 LEUKAPHERESIS PRODUCTS MARKET SHARE, BY KEY PLAYER (2022)
13.6 MARKET SHARE ANALYSIS (LEUKOPAKS, 2022)
TABLE 234 LEUKOPAKS MARKET: DEGREE OF COMPETITION
FIGURE 69 LEUKOPAKS MARKET SHARE, BY KEY PLAYER (2022)
13.7 COMPANY EVALUATION MATRIX, 2022 (LEUKAPHERESIS PRODUCTS MARKET)
13.7.1 STARS
13.7.2 EMERGING LEADERS
13.7.3 PERVASIVE PLAYERS
13.7.4 PARTICIPANTS
FIGURE 70 LEUKAPHERESIS PRODUCTS MARKET: COMPANY EVALUATION MATRIX (2022)
13.8 COMPETITIVE EVALUATION MATRIX FOR START-UPS/SMES (LEUKAPHERESIS MARKET) (2022)
TABLE 235 LEUKAPHERESIS MARKET: KEY START-UPS/SMES
13.8.1 PROGRESSIVE COMPANIES
13.8.2 DYNAMIC COMPANIES
13.8.3 STARTING BLOCKS
13.8.4 RESPONSIVE COMPANIES
FIGURE 71 LEUKAPHERESIS MARKET: SMES/START-UPS COMPANY EVALUATION QUADRANT (2022)
13.9 COMPETITIVE EVALUATION MATRIX, 2022 (LEUKOPAKS MARKET)
13.9.1 STARS
13.9.2 EMERGING LEADERS
13.9.3 PERVASIVE PLAYERS
13.9.4 PARTICIPANTS
FIGURE 72 LEUKOPAKS MARKET: COMPANY EVALUATION MATRIX (2022)
13.10 COMPETITIVE SCENARIO AND TRENDS
TABLE 236 PRODUCT LAUNCHES AND APPROVALS (JANUARY 2019–AUGUST 2023)
TABLE 237 DEALS (JANUARY 2019–AUGUST 2023)
TABLE 238 OTHER DEVELOPMENTS (JANUARY 2019–AUGUST 2023)
14 COMPANY PROFILES
14.1 KEY PLAYERS (LEUKAPHERESIS PRODUCTS MARKET)
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
14.1.1 TERUMO BCT
TABLE 239 TERUMO BCT: COMPANY OVERVIEW
FIGURE 73 TERUMO BCT: COMPANY SNAPSHOT (2022)
14.1.2 FRESENIUS SE & CO. KGAA
TABLE 240 FRESENIUS SE & CO. KGAA: COMPANY OVERVIEW
FIGURE 74 FRESENIUS SE & CO. KGAA: COMPANY SNAPSHOT (2022)
14.1.3 HAEMONETICS CORPORATION
TABLE 241 HAEMONETICS CORPORATION: COMPANY OVERVIEW
FIGURE 75 HAEMONETICS CORPORATION: COMPANY SNAPSHOT (2022)
14.1.4 ASAHI KASEI CORPORATION
TABLE 242 ASAHI KASEI CORPORATION: COMPANY OVERVIEW
FIGURE 76 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2022)
14.1.5 MACOPHARMA SA
TABLE 243 MACOPHARMA SA: COMPANY OVERVIEW
14.1.6 MILTENYI BIOTEC
TABLE 244 MILTENYI BIOTEC: COMPANY OVERVIEW
14.2 OTHER PLAYERS (LEUKAPHERESIS PRODUCTS MARKET)
14.2.1 GUANGZHOU DAJI MEDICAL SCIENCE AND TECHNOLOGY CO. LTD.
TABLE 245 GUANGZHOU DAJI MEDICAL SCIENCE AND TECHNOLOGY CO. LTD.: COMPANY OVERVIEW
14.2.2 MEDICA SPA.
TABLE 246 MEDICA SPA: COMPANY OVERVIEW
14.2.3 PURIBLOOD MEDICAL CO. LTD.
TABLE 247 PURIBLOOD MEDICAL CO. LTD.: COMPANY OVERVIEW
14.2.4 BEIJING ZKSK TECHNOLOGY CO. LTD.
TABLE 248 BEIJING ZKSK TECHNOLOGY CO. LTD.: COMPANY OVERVIEW
14.2.5 SB-KAWASUMI LABORATORIES, INC.
TABLE 249 SB-KAWASUMI LABORATORIES, INC.: COMPANY OVERVIEW
14.2.6 NIKKISO CO., LTD.
TABLE 250 NIKKISO CO., LTD.: COMPANY OVERVIEW
FIGURE 77 NIKKISO CO., LTD.: COMPANY SNAPSHOT (2022)
14.2.7 PALL CORPORATION
TABLE 251 PALL CORPORATION: COMPANY OVERVIEW
14.3 KEY PLAYERS (LEUKOPAKS MARKET)
14.3.1 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
TABLE 252 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY OVERVIEW
FIGURE 78 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT (2022)
14.3.2 DISCOVERY LIFE SCIENCES, INC.
TABLE 253 DISCOVERY LIFE SCIENCES, INC.: COMPANY OVERVIEW
14.3.3 BIOIVT
TABLE 254 BIOIVT: COMPANY OVERVIEW
14.3.4 PRECISION FOR MEDICINE, INC.
TABLE 255 PRECISION FOR MEDICINE, INC.: COMPANY OVERVIEW
14.3.5 STEMEXPRESS, LLC
TABLE 256 STEMEXPRESS, LLC: COMPANY OVERVIEW
14.4 OTHER PLAYERS (LEUKOPAKS MARKET)
14.4.1 LONZA GROUP AG
TABLE 257 LONZA GROUP AG: COMPANY OVERVIEW
FIGURE 79 LONZA GROUP AG: COMPANY SNAPSHOT (2022)
14.4.2 CALTAG MEDSYSTEMS LIMITED
TABLE 258 CALTAG MEDSYSTEMS LIMITED: COMPANY OVERVIEW
14.4.3 ZENBIO, INC.
TABLE 259 ZENBIO, INC.: COMPANY OVERVIEW
14.4.4 STEMCELL TECHNOLOGIES
14.4.5 TRINA BIOREACTIVES AG
14.4.6 ACCEGEN
14.4.7 FIRST CHOICE BIO LLC
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
15 APPENDIX
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
15.3 CUSTOMIZATION OPTIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS
